In silico screening, structure-activity relationship, and biologic evaluation of selective pteridine reductase inhibitors targeting visceral leishmaniasis

Antimicrobial Agents and Chemotherapy

Volumn 55, Issue 2, 2011, Pages 659-666

  Kaur, Jaspreet ^a   Kumar, Pranav ^a   Tyagi, Sargam ^b   Pathak, Richa ^a   Batra, Sanjay ^a   Singh, Prashant ^c   Singh, Neeloo ^a  

^a CENTRAL DRUG RESEARCH INSTITUTE   (India)

^b Connexious Life Sciences ^*  (India)

^c Dayanand Anglo Vedic (PG) College   (India)

Author keywords

[No Author keywords available]

Indexed keywords

2 [(2 CYANO 3 PHENYL ALLYLAMINO)PHENYL METHYL]ACRYLIC ACID ETHYL ESTER; 2 [(2 CYANO 3 PHENYLALLYLAMINO)(4 TRIFLUOROMETHYLPHENYL)METHYL]ACRYLIC ACID ETHYL ESTER; 2 [[2 CYANO 3 (2,4 DICHLORO PHENYL)ALLYLAMINO]PHENYL METHYL]ACRYLIC ACID ETHYL ESTER; 2 [[3 (2 BROMOPHENYL) 2 CYANO ALLYLAMINO]PHENYLMETHYL]ACRYLIC ACID ETHYL ESTER; 2 [[3 (2 CHLOROPHENYL) 2 CYANO ALLYLAMINO]PHENYL METHYL]ACRYLIC ACID ETHYL ESTER; 2 [[3 (4 CHLOROPHENYL) 2 CYANO ALLYLAMINO](TRIFLUOROMETHYL PHENYL)METHYL]ACRYLIC ACID ETHYL ESTER; 7 (2 BROMOBENZYL) 3 METHYL 4 PHENYL 3,4,6,7,8,9 HEXAHYDROPYRIMIDO[1,2 A]PYRIMIDIN 2 ONE; 7 (2,4 DICHLOROBENZYL) 3 METHYL 4 PHENYL 3,4,6,7,8,9 HEXAHYDROPYRIMIDO[1,2 A]PYRIMIDIN 2 ONE; 7 (4 CHLOROBENZYL) 3 METHYL 4 (4 TRIFLUOROMETHYL PHENYL) 3,4,6,7,8,9 HEXAHYDRO PYRIMIDO[1,2 A]PYRIMIDIN 2 ONE; 7 (4 CHLOROBENZYL) 3 METHYL 4 PHENYL 3,4,6,7,8,9 HEXAHYDROPYRIMIDO[1,2 A]PYRIMIDIN 2 ONE; 7 BENZYL 3 METHYL 4 (4 TRIFLUOROMETHEL PHENYL) 3,4,6,7,8,9 HEXAHYDROPYRIMIDO[1,2 A]PYRIMIDIN 2 ONE; 7 BENZYL 3 METHYL 4 PHENYL 3,4,6,7,8,9 HEXAHYDROPYRIMIDO[1,2 A]PYRIMIDIN 2 ONE; GREEN FLUORESCENT PROTEIN; OXIDOREDUCTASE INHIBITOR; RECOMBINANT ENZYME; UNCLASSIFIED DRUG;

AMASTIGOTE; ARTICLE; BAYLIS HILLMAN REACTION; CELL CULTURE; CELL GROWTH; CONTROLLED STUDY; DRUG DESIGN; DRUG EFFICACY; DRUG SAFETY; DRUG SCREENING; DRUG STRUCTURE; DRUG TARGETING; FLOW CYTOMETRY; IC 50; LEISHMANIA DONOVANI; MOLECULAR DOCKING; NONHUMAN; PRIORITY JOURNAL; PROMASTIGOTE; VISCERAL LEISHMANIASIS;

ANIMALS; ANTIPROTOZOAL AGENTS; BINDING SITES; CELL LINE; ENZYME INHIBITORS; FLOW CYTOMETRY; GREEN FLUORESCENT PROTEINS; HUMANS; LEISHMANIA DONOVANI; LEISHMANIASIS, VISCERAL; MACROPHAGES; MICE; MICE, INBRED BALB C; MODELS, MOLECULAR; OXIDOREDUCTASES; PARASITIC SENSITIVITY TESTS; PYRIMIDINONES; RECOMBINANT PROTEINS; STRUCTURE-ACTIVITY RELATIONSHIP; TRANSFECTION;

EID: 78751684265     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00436-10     Document Type: Article

References (25)

1. Barbosa, T. P., et al. 2009. Improved synthesis of seven aromatic Baylis-Hillman adducts (BHA): evaluation against Artemia salina Leach and Leishmania chagasi. Eur. J. Med. Chem. 44:1726-1730.
2. Bello, A. R., B. Nare, D. Freedman, L. Hardy, and S. M. Beverley. 1994. PTR1: a reductase mediating salvage of oxidized pteridines and methotrexate resistance in the protozoan parasite Leishmania major. Proc. Natl. Acad. Sci. U. S. A. 91:11442-11446.
3. Cavazzuti, A., et al. 2008. Discovery of potent pteridine reductase inhibitors to guide antiparasite drug development. Proc. Natl. Acad. Sci. U. S. A. 105:1448-1453.
4. Chappuis, F., et al. 2007. Visceral leishmaniasis: what are the needs for diagnosis, treatment and control? Nat. Rev. Microbiol. 5:873-882.
5. De Souza, R. O. M. A., et al. 2007. High selective leishmanicidal activity of 3-hydroxy-2-methylene-3-(4-bromophenyl) propanenitrile and analogous compounds. Eur. J. Med. Chem. 42:99-102.
6. De Souza, R. O. M. A., B. A. Meireles, L. C. S. Aguiar, and M. L. A. A. Vasconcellos. 2004. Hexamethylenetetramine as a cheap and convenient alternative catalyst in the Baylis-Hillman reaction: synthesis of aromatic compounds with anti-malarial activity. Synthesis 10:1595-1600.
7. Gehlhaar, D. K., et al. 1995. Molecular recognition of the inhibitor AG-1343 by HIV-1 protease: conformationally flexible docking by evolutionary programming. Chem. Biol. 2:317-324.
8. Gourley, D. G., et al. 2001. Pteridine reductase mechanism correlates pterin metabolism with drug resistance in trypanosomatid parasites. Nat. Struct. Biol. 8:521-525.
9. Japertas, P., R. Didziapetris, and A. Petrauskas. 2003. Fragmental methods in the analysis of biological activities of diverse compound sets. Mini Rev. Med. Chem. 3:797-808.
10. Kaur, J., S. Sundar, and N. Singh. 2010. Molecular docking, structure-activity relationship and biologic evaluation of the anticancer drug monastrol as pteridine reductase inhibitor in Leishmania donovani clinical isolate. J. Antimicrob. Chemother. 65:1742-1748.
11. Knighton, D. R., et al. 1994. Structure of and kinetic channelling in bifunctional dihydrofolate reductase-thymidylate synthase. Nat. Struct. Biol. 1:186-194.
12. Kumar, P., et al. 2008. Leishmania donovani pteridine reductase 1: biochemical properties and structure modeling studies. Exp. Parasitol. 120:73-79.
13. Kumar, P., H. Kothari, and N. Singh. 2004. Overexpression in Escherichia coli and purification of pteridine reductase 1 (PTR1) from a clinical isolate of Leishmania donovani. Protein Expr. Purif. 38:228-236.
14. Kundu, M. K., et al. 1999. Antimalarial activity of 3-hydroxyalkyl-2- methylenepropionic acid derivatives. Bioorg. Med. Chem. Lett. 9:731-736.
15. Lye, L. F., M. L. Cunningham, and S. M. Beverley. 2002. Characterization of quinonoid-dihydropteridine reductase (QDPR) from the lower eukaryote Leishmania major. J. Biol. Chem. 41:38245-38253.
16. Manandhar, K. D., et al. 2008. Antileishmanial activity of nano-amphotericin B deoxycholate. J. Antimicrob. Chemother. 62:376-380.
17. Murray, H. W., J. D. Berman, C. R. Davies, and N. G. Saravia. 2005. Advances in leishmaniasis. Lancet 366:1561-1577.
18. Nare, B., L. Hardy, and S. M. Beverley. 1997. The roles of pteridine reductase 1 and dihydrofolate reductase-thymidylate synthase in pteridine metabolism in the protozoan parasite Leishmania major. J. Biol. Chem. 272:13883-13891.
19. Nare, B., J. Luba, L. W. Hardy, and S. Beverley. 1997. New approaches to Leishmania chemotherapy: pteridine reductase 1 (PTR1) as a target and modulator of antifolate sensitivity. Parasitology 114:S101-S110.
20. Pathak, R., and S. Batra. 2007. Expeditious synthesis of 5,6,7,8-tetrahydroimidazo-[1,2-a]pyrimidin-2-ones and 3,4,6,7,8,9-hexahydro- pyrimido-[1,2-a]pyrimidin-2-ones. Tetrahedron 63:9448-9455.
21. Sali, A., and T. L. Blundell. 1993. Comparative protein modeling by satisfaction of spatial restraints. J. Mol. Biol. 234:779-815.
22. Shallom, S., K. Zhang, L. Jiang, and P. K. Rathod. 1999. Essential protein-protein interactions between Plasmodium falciparum thymidylate synthase and dihydrofolate reductase domains. J. Biol. Chem. 274:37781-37786.
23. Singh, N., and A. Dube. 2004. Fluorescent Leishmania: application to antileishmanial drug testing. Am. J. Trop. Med. Hyg. 71:400-402.
24. Sundar, S., and M. Chatterjee. 2006. Visceral leishmaniasis-current therapeutic modalities. Indian J. Med. Res. 123:345-352.
25. Zuccotto, F., A. C. R. Martin, R. A. Laskowski, J. M. Thornton, and I. H. Gilbert. 1998. Dihydrofolate reductase: a potential drug target in trypanosomes and leishmania. J. Comput.-Aided Mol. Des. 12:241-257.